Full View

Erlotinib might be a double‐edged sword in HCC

JZ Dong, LP Wang, SN Zhang, ZL Zou, MQ Lu - Hepatology, 2015 - journals.lww.com
In a recent issue of HEPATOLOGY, Fuchs et al. 1 reported that the epidermal growth factor
receptor (EGFR) inhibitor erlotinib could effectively prevent the progression of cirrhosis and …
被引用次数：3 相关文章

Reply: Erlotinib might be a double-edged sword in HCC

BC Fuchs, Y Hoshida, KK Tanabe - Hepatology (Baltimore, Md.), 2015 - ncbi.nlm.nih.gov
We appreciate the interest of Dong et al. in our recent article. 1 As they point out,
hepatocellular carcinoma (HCC) cell lines are largely resistant to erlotinib at clinically …

[引用][C] Erlotinib might be a double-edged sword in HCC

JZ Dong, LP Wang, SN Zhang… - Hepatology …, 2015 - pubmed.ncbi.nlm.nih.gov

[引用][C] Erlotinib might be a double‐edged sword in HCC

JZ Dong, LP Wang, SN Zhang, ZL Zou, MQ Lu - Hepatology, 2015 - infona.pl
Erlotinib might be a double‐edged sword in HCC × Close The Infona portal uses cookies, ie
strings of text saved by a browser on the user's device. The portal can access those files and …

Erlotinib might be a double‐edged sword in HCC

JZ Dong, LP Wang, SN Zhang, ZL Zou, MQ Lu - Hepatology, 2015 - Wiley Online Library
In a recent issue of HEPATOLOGY, Fuchs et al. 1 reported that the epidermal growth factor
receptor (EGFR) inhibitor erlotinib could effectively prevent the progression of cirrhosis and …

[引用][C] Erlotinib might be a double-edged sword in HCC.

JZ Dong, LP Wang, SN Zhang, ZL Zou… - Hepatology (Baltimore …, 2014 - europepmc.org
A comment on this article appears in" Reply: To PMID 24677197." Hepatology. 2015 Feb; 61
(2): 729-30. This is a comment on" Epidermal growth factor receptor inhibition attenuates …